Nanjing Well Pharmaceutical Co Ltd Total Assets
Nanjing Well Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) holds total assets worth CN¥2.63 Billion CNY (≈ $384.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Nanjing Well Pharmaceutical Co Ltd (603351) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Total assets of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Nanjing Well Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Nanjing Well Pharmaceutical Co Ltd - Asset Composition Analysis
Nanjing Well Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Nanjing Well Pharmaceutical Co Ltd total assets breakdown as of December 2025. Nanjing Well Pharmaceutical Co Ltd's total assets of CN¥2.63 Billion consist of 34.9% current assets and 65.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.3% |
| Accounts Receivable | CN¥200.27 Million | 7.7% |
| Inventory | CN¥206.11 Million | 8.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥107.68 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Nanjing Well Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing Well Pharmaceutical Co Ltd's current assets represent 34.9% of total assets in 2025, a decrease from 44.8% in 2014.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2025, up from 6.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 10.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 8.0% of total assets.
Nanjing Well Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nanjing Well Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Nanjing Well Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.26 | 1.23 |
| Quick Ratio | 1.10 | 0.92 | 0.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥268.77 Million | CN¥151.75 Million | CN¥81.59 Million |
Nanjing Well Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing Well Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 8.9% |
| Total Assets | CN¥2.59 Billion |
| Market Capitalization | $534.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing Well Pharmaceutical Co Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nanjing Well Pharmaceutical Co Ltd's assets grew by 8.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nanjing Well Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual total assets of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.59 Billion ≈ $379.56 Million |
+8.94% |
| 2024-12-31 | CN¥2.38 Billion ≈ $348.40 Million |
+4.48% |
| 2023-12-31 | CN¥2.28 Billion ≈ $333.48 Million |
+6.58% |
| 2022-12-31 | CN¥2.14 Billion ≈ $312.88 Million |
+16.11% |
| 2021-12-31 | CN¥1.84 Billion ≈ $269.46 Million |
+12.53% |
| 2020-12-31 | CN¥1.64 Billion ≈ $239.46 Million |
+12.22% |
| 2019-12-31 | CN¥1.46 Billion ≈ $213.39 Million |
+80.43% |
| 2018-12-31 | CN¥808.20 Million ≈ $118.26 Million |
+11.40% |
| 2017-12-31 | CN¥725.52 Million ≈ $106.17 Million |
+20.87% |
| 2016-12-31 | CN¥600.23 Million ≈ $87.83 Million |
+23.12% |
| 2015-12-31 | CN¥487.50 Million ≈ $71.34 Million |
+16.27% |
| 2014-12-31 | CN¥419.30 Million ≈ $61.36 Million |
-- |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3… Read more